Primary cancer prevention trials

Hematology/Oncology Clinics of North America

Volumn 14, Issue 4, 2000, Pages 809-830

  Hawk, Ernest T ^a   Lippman, Scott M ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANTILIPEMIC AGENT; ANTIOXIDANT; BETA CAROTENE; CALCIUM CARBONATE; CLOFIBRATE; COLESTIPOL; COLESTYRAMINE; FOLIC ACID; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; PROBUCOL; PROSTAGLANDIN SYNTHASE INHIBITOR; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SELENIUM; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMOXIFEN;

ARTHRITIS; BREAST CANCER; CANCER; CANCER EPIDEMIOLOGY; CANCER PREVENTION; CANCER RESEARCH; CARDIOVASCULAR DISEASE; CLINICAL RESEARCH; CLINICAL TRIAL; COLON CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HEAD AND NECK CANCER; HUMAN; HYPERLIPIDEMIA; LUNG CANCER; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; REVIEW;

EID: 0033887511     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(05)70313-0     Document Type: Article

References (112)

1. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers
2. Calcium supplements for the prevention of colorectal adenomas
3. Compliance issues/biological markers
4. Linxian nutrition intervention trials: Supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population
5. Properties of intraepithelial neoplasia relevant to the development of cancer chemopreventive agents
6. The environment and disease: Association and causation
7. Users' guides to the medical literature. XIX. Applying clinical trial results - How to use an article measuring the effect of an intervention on surrogate end points
8. Summary of the study design
9. Chemoprevention Clinical Trials - Problems and Solutions
10. American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: Tamoxifen and raloxifene
11. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin
12. Physical activity and reduced risk of colon cancer: Implications for prevention
13. The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial
14. Health-related quality of life and tamoxifen in breast cancer prevention: A report from the National Surgical Adjuvant Breast and Bowel Project P-1 study
15. Rationale and mechanisms of cancer chemoprevention
16. A recent emphasis in the Prevention Program of the National Cancer Institute
17. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels
18. Tamoxifen for early breast cancer: An overview of the randomized trials
19. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
20. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial
21. Clinical Epidemiology: The Essentials
22. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer
23. Low-dose aspirin and incidence of colorectal tumors in a randomized trial
24. Methodological issues in the design of primary prevention trials
25. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis
26. Selective cyclooxygenase-2 inhibitors
27. Lipid-lowering therapy for the primary prevention of coronary heart disease
28. Powerful tools for genetic analysis come of age
29. A clinical trial of β-carotene to prevent basal-cell and squamous-cell cancers of the skin
30. A clinical trial of antioxidant vitamins to prevent colorectal adenoma
31. Chemoprevention in the 21st century
32. Pharmacoeconomics of lipid-lowering agents for primary and secondary prevention of coronary artery disease
33. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials
34. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents
35. Update on aspirin in the treatment and prevention of cardiovascular disease
36. Lessons from hypertension trials
37. Validity versus generalizability in clinical trial design and conduct
38. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease
39. A primary prevention trial using nutritional doses of antioxidant vitamins and minerals in cardiovascular diseases and cancers in a general population: The SU.VI.MAX study - Designs, methods, and participant characteristics
40. The impact of social class on the use of cancer screening within three racial/ethnic groups in the United States
41. Chemoprevention of head and neck cancer. Potential use of retinoids
42. 13-cis-retinoic acid in the treatment of oral leukoplakia
43. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck
44. Recent advances in chemoprevention of cancer
45. Immunoprevention of cancer poses a challenge to pharmacological research
46. The recent decline in mortality from coronary heart disease, 1980- 1990: The effect of secular trends in risk factors and treatment
47. Progress in clinical chemoprevention
48. Approaches to the development and marketing approval of drugs that prevent cancer
49. Chemoprevention of colorectal cancer
50. Interim analysis of randomized chemoprevention trial of HNSCC
51. Preface
52. A Dictionary of Epidemiology
53. Drugs used in the treatment of hyperlipoproteinemias
54. Nutrition intervention trials in Linxian, China: Multiple vitamin/mineral supplementation, cancer incidence, and disease-specific mortality among adults with esophageal dysplasia
55. Comparison of low-dose isotretinoin with β-carotene to prevent oral carcinogenesis
56. Cancer chemoprevention
57. Tamoxifen prevention of breast cancer: An instance of the fingerpost
58. Phase III Intergroup trial of 13-cis-retinoic acid to prevent second primary tumors in stage I non-small cell lung cancer (NSCLC): Interim Report of NCI#119-0001
59. Biomarkers as intermediate end points in chemoprevention trials
60. Cancer chemoprevention - Progress and promise
61. Suppression of retinoic acid receptor β in premalignant oral lesions and its upregulation by isotretinoin
62. Efficacy of interventions designed to inhibit the progression of coronary atherosclerosis
63. The late-stage diagnosis of colorectal cancer: Demographic and socioeconomic factors
64. The primary prevention of myocardial infarction
65. Frequent microsatellite alterations at chromosome 9p21 and 3p14 in oral premalignant lesions and its value in cancer risk assessment
66. Design and baseline characteristics of study participants in the Wheat Bran Fiber trial
67. National Cancer Institute-supported cancer chemoprevention research: Coming of age
68. A randomized trial of a low fat high fiber diet in the recurrence of colorectal polyps. Toronto Polyp Prevention Group
69. Exercise clinical trials in cancer prevention research: A call to action
70. Vitamins and other therapeutic nutritional agents-Treatment of hyperlipidemia and atherosclerosis
71. Chemoprevention of human cancer: A reasonable strategy?
72. Principles of human chemoprevention
73. Effect of retinol in preventing squamous cell skin cancer in moderate-risk subjects: A randomized, double-blind, controlled trial
74. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease
75. Experimental pathology and breast cancer genetics: New technologies
76. Co-carcinogenic effect of β-carotene
77. Colestid (colestipol hydrochloride for oral suspension)
78. Lorelco (probucol)
79. Mevacor (lovastatin)
80. Pravachol (pravastatin sodium tablets)
81. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial
82. Surrogate end points, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease
83. Nonsteroidal anti-inflammatory drugs in Alzheimer's disease
84. Effects of long-term sulindac therapy on colonic polyposis
85. Nutritional factors in cancer prevention
86. Effects of health insurance and race on early detection of cancer
87. Trends in the incidence of myocardial infarction and in mortality due to coronary heart disease, 1987 to 1994
88. Validation of intermediate end points in cancer research
89. Surrogate end points in cancer research: A critique
90. The polyp prevention trial I: Rationale, design, recruitment, and baseline participant characteristics
91. Safety considerations in the conduct of chemoprevention trials
92. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
93. Laser-capture microdissection: Opening the microscopic frontier to molecular analysis
94. Colorectal cancer and nonsteroidal anti-inflammatory drugs
95. Approaches to prevention of epithelial cancer during the preneoplastic period
96. The war on cancer: A review
97. Aspirin use and colorectal cancer: Post-trial follow-up data from the Physicians' Health Study
98. Recruitment: A perspective for multicenter clinical trials
99. Are surrogate markers adequate to assess cardiovascular disease drugs?
100. Methodology
101. Aspirin prophylaxis for the primary prevention of myocardial infarction
102. A randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer
103. Prevention of breast cancer with tamoxifen: Preliminary findings from the Italian randomised trial among hysterectomised women
104. Head and neck cancer
105. Retinoid signaling and activator protein-1 expression in ferrets given β-carotene supplements and exposed to tobacco smoke
106. Chemoprophylaxis of carcinogenesis: A review
107. An overview of chemoprevention: Current status and future prospects
108. Selective estrogen receptor modulators
109. Cigarette smoking as a risk factor for coronary artery disease
110. Prevention of colorectal cancer by colonoscopic polypectomy
111. Effective treatment of early endobronchial cancer with regional administration of liposome-p53 complexes